Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

25.86 -0.99 (-3.67%)
Streaming Delayed Price Updated: 10:09 AM EDT, Oct 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna, Inc. - Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Moderna to Present at Upcoming Conferences in November 2024
Via ACCESSWIRE
Behind the Scenes of Moderna's Latest Options Trends
 
Via Benzinga
Why Is Moderna Stock Trading Higher On Monday?
Merck and Moderna initiate Phase 3 trial of mRNA-4157 (V940) with Keytruda as adjuvant for NSCLC patients, marking progress in individualized cancer therapies. 
Via Benzinga
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Large-Cap Stocks In Trouble - Sunday, Oct. 27
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Moderna Unusual Options Activity For October 22
 
Via Benzinga
A Closer Look at Moderna's Options Market Dynamics
 
Via Benzinga
Moderna Named a Top Employer by Science for Tenth Consecutive Year
Via ACCESSWIRE
How Bad Is This News for Novavax?
Novavax stock fell 20% in one trading session on the news. 
Via The Motley Fool
Large-Cap Stocks In Trouble - Saturday, Oct. 19
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
Benzinga Bulls And Bears: Apple, Tesla, Netflix, Oklo — And Dogecoin, Meme Coins Outpace Corporate Giants
Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. 
Via Benzinga
Goldman Sachs Highlights 20 Top Short-Squeeze Opportunities For Q3 Earnings Season
Goldman Sachs identified 20 stocks with high short interest that could be primed for a short squeeze. Hint: A pet retailer tops the chart. 
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,900 Today
 
Via Benzinga
Netflix, TSMC, American Express, Moderna, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
S. markets ended Thursday with mixed performance: the Dow Jones Industrial Average climbed 0.4% to 43,239.05. 
Via Benzinga
Topics Stocks
Moderna Hit With Another Lawsuit Related To Key COVID-19 Vaccine Technology
Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle technology without permission in the development of its COVID-19 vaccines. 
Via Benzinga
Topics Lawsuit
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Via ACCESSWIRE
Cathie Wood Continues To Sell Shares Of Jack Dorsey's Bitcoin-Focused Company Block — Ark Also Dumps Moderna, Robinhood Stock
On Wednesday, Cathie Wood’s Ark Invest made significant trades involving Block Inc (NYSE:SQ) and Moderna Inc (NASDAQ:MRNA). The SQ Trade 
Via Benzinga
Cathie Wood's Ark Offloads $1.28M In Jack Dorsey's Block Shares Despite Bitcoin Rally
On Tuesday, Cathie Wood-led Ark Invest made significant trades, most notably selling off shares of Block Inc. (NYSE:SQ). The SQ Trade 
Via Benzinga
Unveiling 18 Analyst Insights On Moderna
 
Via Benzinga
(MRNA) - Analyzing Moderna's Short Interest
 
Via Benzinga
GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement
GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine... 
Via Benzinga
Topics Intellectual Property Lawsuit
The Bull's Biggest Hits And Misses
The bull market turned two years old over the weekend. Here are some of the S&P 500's biggest winners and losers over the last two years. 
Via Talk Markets
Topics Stocks
Large-Cap Stocks In Trouble - Sunday, Oct. 13
Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns. 
Via Talk Markets
2 Biotech Stocks That Are Screaming Buys This Month
They won't remain southbound forever. 
Via The Motley Fool
Cathie Wood's Ark Invest Dumps Over $9M In Moderna Stock — Even With Post-COVID Plans On The Table
On Thursday Oct 10, 2024 Cathie Wood-Led Ark Invest sold over $9 million worth of Moderna stock. 
Via Benzinga
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could... 
Via Benzinga
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Eleven large-cap stocks were worst performers last week. Decline in Stars performance and sales, regulations and supply issues caused the drop. 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.